The trial, ACTT-2, examined the safety and efficacy of a combination of remdesivir and baricitinib for hospitalized COVID-19 patients.

Thursday, October 8, 2020 New Data Presented from Trial of Remdesivir Plus Baricitinib for COVID-19 Today, John Beigel, M.D., associate director for clinical research in the Division of Microbiology and Infectious Diseases at NIAID, presented new data from a trial examining the safety and efficacy of a combination of remdesivir and baricitinib for hospitalized COVID-19 patients (ACTT-2). The presentation, which was given during the Special isirv-AVG Virtual Conference on Therapeutics for COVID-19, expanded on the primary results of the trial which were announced earlier this year, which indicated that the combination of remdesivir and baricitinib reduced time to recovery in hospitalized patients. Dr. Beigel noted that participants' condition at Day 15 of their participation in the trial was improved when they received the combination of the two therapeutics. Patients who required oxygen during their hospitalization appear to have received the largest benefit for the treatment. Investigators are completing their full analysis of the results, and a manuscript in a peer-reviewed publication will be available soon. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107